EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers. Morphotek will apply its proprietary MORPHODOMA® antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer.
